RxDoctor Payments DataLook up a doctor →

Fahed Bitar, MD

Interventional Cardiology · Covina, CANPI 1174728612

Payments from drug & device makers

$9,857,448in general payments, 2019–2025

Across 2,183 payments — averaging $4515.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$4.1M
  • Novartis$2.2M
  • CSL Behring$1.2M
  • Novo Nordisk AS$552K
  • Modernatx, Inc.$519K
  • American Regent$511K
  • plus $877K from 54 others
$230,951in research payments, 2019–2025

Across 19 payments — averaging $12,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$231K
  • Abiomed$219

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly83$4,051,090
Novartis225$2,180,173
CSL Behring144$1,166,857
Novo Nordisk AS761$552,045
Modernatx, Inc.33$519,032
American Regent38$511,189
Merck41$227,851
Alnylam Pharmaceuticals Inc.53$165,722
Astrazeneca UK Limited7$163,293
Amgen45$103,554
Boehringer Ingelheim International GmbH29$77,359
Boehringer Ingelheim Pharma GmbH & Co.kg5$44,215
Bayer13$34,086
Regeneron1$17,500
AstraZeneca33$14,954
E.r. Squibb & Sons, L.L.C.44$12,065
Abbott58$2,826
Abiomed81$2,120
Edwards Lifesciences31$1,544
Pfizer87$1,512
Medtronic(2 entities)46$1,355
Boston Scientific54$1,322
Novo Nordisk28$636
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)50$629
Shockwave Medical, Inc25$571
Johnson & Johnson28$506
Amarin Pharma, Inc.19$396
Boehringer Ingelheim17$344
Impulse Dynamics (USA) Inc.4$257
Lexicon Pharmaceuticals, Inc.13$236
Cardiva Medical, Inc.2$224
Esperion Therapeutics, Inc.10$217
Atricure, Inc.2$194
Sanofi-aventis U.S. LLC11$179
Kiniksa Pharmaceuticals International, PLC7$174
Kowa Pharmaceuticals America, Inc.9$161
Kestra Medical Technology Services, Inc.5$125
Inspire Medical Systems, Inc.5$96
Kiniksa Pharmaceuticals, Ltd.4$71
Teleflex LLC3$65
Cleerly, Inc.1$64
Akcea Therapeutics, Inc.3$64
Stryker2$60
Arbor Pharmaceuticals, Inc.3$57
Philips North America LLC2$49
Chiesi USA, Inc.2$45
Braemar Manufacturing, LLC1$42
Regeneron Healthcare Solutions, Inc.2$42
Cardiovascular Systems Inc.1$36
Lilly USA, LLC1$31
Heartflow, Inc.1$29
Scpharmaceuticals Inc.1$26
Biotronik Inc.1$24
Cvrx, Inc.1$22
Livanova USA, Inc.1$22
Actelion Pharmaceuticals US, Inc.1$19
Tactile Systems Technology Inc1$18
Altathera Pharmaceuticals LLC1$16
AbbVie1$14
Bard Peripheral Vascular, Inc.1$12

How this compares

$9,857,448 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$516,609
Medicare patients
1,217
Services billed
5,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Covina

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →